関連する実験動画
Updated: May 6, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
トロンビン-トロンボモジュリン複合体の抗凝固作用の構造的基礎
P Fuentes-Prior1, Y Iwanaga, R Huber
1Max-Planck-Institut für Biochemie, Martinsried, Germany. fuentes@biochem.mpg.de
Nature
|April 13, 2000
まとめ
アルファトロンビンと結合するトロンボモジュリン (TME456) は,基質の特異性を変化させることで,血液の凝固を防ぐ. この構造的な洞察は,TME456が,血栓活性部位を変えることなく,抗凝固剤のタンパク質Cの活性化を促進する方法を明らかにします.
科学分野:
- バイオケミストリー バイオケミストリー
- 構造生物学 構造生物学とは
- 血液学 ヘマトロジ
背景:
- アルファトロンビンは,血液凝固の重要な酵素であり,血栓形成を促進します.
- トロンボモジュリンは,トロンビンの活性を調節し,タンパク質Cを活性化することによって,それを抗凝固にシフトさせます.
- 活性化タンパク質Cは,活性化因子VとVIIIを分解することによって,凝固カスケードを調節する.
研究 の 目的:
- TME456トロンボモジュリン断片に結合したヒトアルファトロンビンの結晶構造を決定するために.
- トロンボモドゥリンがトロンビンの基板特異性を変化させるメカニズムを解明する.
主な方法:
- 2.3A解像度でアルファトロンビン-TME456複合体のX線結晶学.
- 複合体へのタンパク質Cモデルの分子ドッキング.
主要な成果:
- Y形のTME456断片は,トロンビンのアニオン結合エクソサイト-Iに結合し,ステリカルにプロコアグラント基板へのアクセスを阻害します.
- トロンビンの活性部位の構造は,TME456結合時にほとんど変化しません.
- ドッキングにより,TME456はタンパク質Cを最適に配置し,未変化のトロンビン活性部位によって活性化することが示唆される.
結論:
- この構造は,トロンボモジュリンのエクソサイト-Iへの結合が,トロンビンの機能をプロコアグラントから抗凝固剤にリダイレクトする方法を示しています.
- このメカニズムは,プロコアグラント基質のアロステリック阻害と活性化のためのタンパク質Cの最適なプレゼンテーションを含む.
さらに関連する動画
関連する概念動画
Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Coagulation
8.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.5K
Extrinsic and Intrinsic Pathways of Hemostasis
11.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.0K
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K

